Y Simonin, N Erkilic, K Damodar, M Clé, C Desmetz, K Bolloré, M Taleb, S Torriano, J Barthelemy, G Dubois, A D Lajoix, V Foulongne, E Tuaillon, P Van de Perre, V Kalatzis, S Salinas
Ebola, état des lieux des projets de recherche menés dans le cadre de REACTing en 2015
To clarify the role of bats in the ecology of Ebola viruses, we assessed the prevalence of Ebola virus antibodies in a large-scale sample of bats collected during 2015–2017 from countries in Africa that have had previous Ebola outbreaks (Guinea, the Democratic Republic of the Congo) or are at high risk for outbreaks (Cameroon). Certain bat species widespread across Africa had serologic evidence of Zaire and Sudan Ebola viruses.
Il y a 4 ans sévissait la plus dévastatrice épidémie d’Ebola en Afrique de l’Ouest. Les reporters de TV5 Monde sont retournés en Guinée, pays du patient zéro. La population est encore traumatisée par un fléau qui a tué 11 000 personnes, et contre lequel la seule défense qui existe, est un vaccin expérimental.
Matusali G, Houzet L, Satie AP, Mahé D, Aubry F, Couderc T, Frouard J, Bourgeau S, Bensalah K, Lavoué S, Joguet G, Bujan L, Cabié A, Avelar G, Lecuit M, Le Tortorec A, Dejucq-Rainsford N
In 2016, Guinea, Liberia and Sierra Leone succeeded in interrupting the longest epidemic of Ebola virus disease in global history. However, the risk of re-emergence of Ebola virus disease is real, as shown by the 2017 and 2018 outbreaks in the Democratic Republic of the Congo. Consequently, along with other public health measures, efforts to develop an effective vaccine against Ebola virus disease must continue.
The number of plague cases has been steadily increasing over the past 30 years and Madagascar has gone through an unprecedented epidemic episode in 2017. In response, REACTing from Inserm, the Pasteur Institute of Madagascar and the International Network of the Institut Pasteur organized, on 9 and 10 July 2018, an international workshop to define research priorities on this disease.
Experimental treatments are being considered to cope with the current Ebola outbreak in the Democratic Republic of Congo. An experimental vaccine is already being administered.
In France, considerations around experimental treatments are notably lead within the REACTing platform of Inserm, in collaboration with the research institutes grouped under the Alliance for Life Sciences and Health (Aviesan).
Placide Mbala Kingebeni, Christian-Julian Villabona-Arenas, Nicole VidalJacques Likofata, Justus Nsio-Mbeta, Sheila Makiala-Mandanda, Daniel MukadiPatrick Mukadi, Charles Kumakamba, Bathe Djokolo, Ahidjo Ayouba, Eric Delaporte, Martine Peeters, Jean-Jacques Muyembe Tamfum, Steve Ahuka Mundeke